Update on the utility of prognostic biomarkers in ovarian cancer
Open Access
- 29 April 2009
- journal article
- Published by H1 Connect in F1000 Medicine Reports
- Vol. 1 (31)
- https://doi.org/10.3410/m1-31
Abstract
Update on the utility of prognostic biomarkers in ovarian cancerThis publication has 10 references indexed in Scilit:
- CA‐125 change after chemotherapy in prediction of treatment outcome among advanced mucinous and clear cell epithelial ovarian cancersCancer, 2009
- Dicer, Drosha, and Outcomes in Patients with Ovarian CancerThe New England Journal of Medicine, 2008
- Prediction of ovarian cancer prognosis and response to chemotherapy by a serum-based multiparametric biomarker panelBritish Journal of Cancer, 2008
- DNA methylation changes in ovarian cancer: Implications for early diagnosis, prognosis and treatmentGynecologic Oncology, 2008
- Correlation of NK T-like CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNFα in ascites from advanced ovarian cancer: Association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapyGynecologic Oncology, 2008
- A Multiparametric Panel for Ovarian Cancer Diagnosis, Prognosis, and Response to ChemotherapyClinical Cancer Research, 2007
- Whole Genome Oligonucleotide-Based Array Comparative Genomic Hybridization Analysis Identified Fibroblast Growth Factor 1 As a Prognostic Marker for Advanced-Stage Serous Ovarian AdenocarcinomasJournal of Clinical Oncology, 2007
- Expression of TAG-72 in ovarian cancer and its correlation with tumor stage and patient prognosisCancer Letters, 2007
- Intraepithelial CD8+tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancerProceedings of the National Academy of Sciences of the United States of America, 2005
- Gene Expression Profiles Associated with Response to Chemotherapy in Epithelial Ovarian CancersClinical Cancer Research, 2005